Preferred therapies for neovascular age-related macular degeneration
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Purpose of review This report reviews the current treatment strategies and the most recent clinical trials in the treatment of neovascular age-related macular degeneration. Recent findings The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Additionally, level I evidence now exists for the noninferiority of bevacizumab, as compared to ranibizumab, in the treatment of neovascular age-related macular degeneration (AMD) through 1 year of follow-up. Aflibercept has emerged as a new anti- vascular endothelial growth factor (VEGF) therapy showing encouraging treatment results at 1 year. Novel treatments combined with anti-VEGF agents such as localized radiation are currently being investigated. Summary Anti-VEGF monotherapy remains the preferred therapy for the management of neovascular AMD at the present time. Aflibercept is a new, FDA-approved, effective, anti-VEGF agent available for clinical use. Ongoing clinical trials will help determine the optimal dosing regimens for all of these agents, as well as the long-term efficacy and safety of combination therapy modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Current concepts in the pathogenesis of age-related macular degeneration
Zarbin, M. A. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.598 · Cited by 1,006 · cited 1×
“The pathophysiology of CNV is complex, involving both angiogenesis and vasculogenesis [48,49].”
BackgroundRegillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
Self-citation(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
Self-citationCigarette Smoking and Age-Related Macular Degeneration in the EUREYE Study
Chakravarthy, U., Augood, C., Bentham, G. C., de Jong, P. T. V. M., Rahu, M., Seland, J., Soubrane, G., Tomazzoli, L., Topouzis, F., Vingerling, J. R., et al. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.022 · Cited by 230 · cited 1×
“In the USA, age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in those over 65 years of age [1,2].”
Background
Cited by
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Self-citationMechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382
“Since the newer agents outperformed pegatinib in improving visual outcome, they have become the standard of care for NVAMD in the clinic [33,63].”
BackgroundCancer prevention by targeting angiogenesis
Albini, A., Tosetti, F., Li, V. W., Noonan, D. M., & Li, W. W. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.120 · Cited by 306
Dry Age-Related Macular Degeneration: Mechanisms, Therapeutic Targets, and Imaging
Bowes Rickman, C., Farsiu, S., Toth, C. A., & Klingeborn, M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12757 · Cited by 282
Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.12.018 · Cited by 88
Metadata
- Authors
- Lally, D. R., Gerstenblith, A. T., & Regillo, C. D.
- Venue
- Current Opinion in Ophthalmology
- Published
- 2012-05
- Volume
- 23
- Issue
- 3
- Pages
- 182-188
- ISSN
- 1040-8738 (ISSN-L)
- OpenAlex
- W4230511471
- Cited by
- 47
- References
- 11
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preferred therapies for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1097/icu.0b013e328352411c
- The paper
- Lally, D. R., Gerstenblith, A. T., & Regillo, C. D. (2012). Preferred therapies for neovascular age-related macular degeneration. Current Opinion in Ophthalmology. https://doi.org/10.1097/icu.0b013e328352411c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.